James Gilligan
President at TRYPTAMINE THERAPEUTICS LIMITED
Net worth: - $ as of 2024-04-29
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Agnes Olszewski | M | 67 | 22 years | |
| James Kuo | M | 58 | 5 years | |
| Peter Molloy | M | 52 | 4 years | |
| Philip Jull | M | 64 | 4 years | |
| Sidney Taubenfeld | M | - | 2 years | |
| David S. Krause | M | - |
Tarsa Therapeutics, Inc.
 Tarsa Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Tarsa Therapeutics, Inc. engages in the development of therapies for the treatment and prevention of osteoporosis and related bone diseases. Its product OSTORA, is an oral formulation of calcitonin, which is a recombinant peptide hormone that inhibits bone resorption. The company was founded by David Brand and James Gilligan in 2009 and is headquartered in Philadelphia, PA. | 14 years |
| Michael Silverman | M | - | - | |
| Christopher Ntoumenopoulos | M | - | 2 years | |
| Peter Guzzo | M | - | 4 years | |
| James O’Neill | M | 64 | 2 years | |
| Jason Carroll | M | - | 1 years |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Garner William | M | 58 | 3 years | |
| Gregory M. McKee | M | 60 | 1 years | |
| Dave Tousley | M | 69 | 1 years | |
| Don Soland | M | 65 |
Tarsa Therapeutics, Inc.
Tarsa Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Tarsa Therapeutics, Inc. engages in the development of therapies for the treatment and prevention of osteoporosis and related bone diseases. Its product OSTORA, is an oral formulation of calcitonin, which is a recombinant peptide hormone that inhibits bone resorption. The company was founded by David Brand and James Gilligan in 2009 and is headquartered in Philadelphia, PA. | - |
| George R. Maurer | M | 68 |
Tarsa Therapeutics, Inc.
Tarsa Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Tarsa Therapeutics, Inc. engages in the development of therapies for the treatment and prevention of osteoporosis and related bone diseases. Its product OSTORA, is an oral formulation of calcitonin, which is a recombinant peptide hormone that inhibits bone resorption. The company was founded by David Brand and James Gilligan in 2009 and is headquartered in Philadelphia, PA. | 5 years |
| Nicholas LaBella | M | 68 |
Tarsa Therapeutics, Inc.
Tarsa Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Tarsa Therapeutics, Inc. engages in the development of therapies for the treatment and prevention of osteoporosis and related bone diseases. Its product OSTORA, is an oral formulation of calcitonin, which is a recombinant peptide hormone that inhibits bone resorption. The company was founded by David Brand and James Gilligan in 2009 and is headquartered in Philadelphia, PA. | 3 years |
| Terese Gieselman | F | 62 | 1 years | |
| Thomas D'Orazio | M | - | - | |
| Luke Hayes | M | - | - | |
| Lawrence Woo | M | - | - | |
| Joy Willis | F | - | 1 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| Canada | 16 | 72.73% |
| United States | 6 | 27.27% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- James Gilligan
- Personal Network
